Kingfisher Capital LLC Invests $1,376,000 in Celgene Corporation (CELG)

Kingfisher Capital LLC acquired a new position in Celgene Corporation (NASDAQ:CELG) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 13,166 shares of the biopharmaceutical company’s stock, valued at approximately $1,376,000.

A number of other institutional investors have also recently made changes to their positions in the company. First Financial Corp IN raised its position in shares of Celgene Corporation by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 228 shares during the last quarter. Smithfield Trust Co. raised its position in shares of Celgene Corporation by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 142 shares during the last quarter. Jolley Asset Management LLC raised its position in shares of Celgene Corporation by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 25 shares during the last quarter. Integrated Investment Consultants LLC raised its position in shares of Celgene Corporation by 2.2% in the third quarter. Integrated Investment Consultants LLC now owns 1,369 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 30 shares during the last quarter. Finally, Cornerstone Advisors Inc. raised its position in shares of Celgene Corporation by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 884 shares during the last quarter. Institutional investors own 77.16% of the company’s stock.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Shares of Celgene Corporation (NASDAQ:CELG) traded down 0.97% during trading on Friday, reaching $115.61. 3,102,837 shares of the company’s stock were exchanged. The stock has a market cap of $89.62 billion, a P/E ratio of 46.43 and a beta of 1.74. Celgene Corporation has a 12-month low of $94.39 and a 12-month high of $127.00. The company has a 50 day moving average of $116.15 and a 200 day moving average of $111.71.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.02. Celgene Corporation had a net margin of 17.80% and a return on equity of 77.95%. The business earned $2.98 billion during the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter in the prior year, the business posted $1.18 EPS. The company’s revenue for the quarter was up 16.3% on a year-over-year basis. Equities research analysts anticipate that Celgene Corporation will post $7.22 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Kingfisher Capital LLC Invests $1,376,000 in Celgene Corporation (CELG)” was posted by sleekmoney and is the sole property of of sleekmoney. If you are accessing this report on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be read at http://sleekmoney.com/kingfisher-capital-llc-invests-1376000-in-celgene-corporation-celg/1657003.html.

A number of equities analysts recently weighed in on the stock. Vetr lowered shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $129.09 price objective for the company. in a report on Wednesday, December 14th. Oppenheimer Holdings, Inc. assumed coverage on shares of Celgene Corporation in a research note on Tuesday, November 29th. They set an “outperform” rating and a $141.00 target price for the company. Piper Jaffray Companies reiterated a “buy” rating on shares of Celgene Corporation in a research note on Tuesday, October 18th. BMO Capital Markets reiterated an “outperform” rating and set a $142.00 target price on shares of Celgene Corporation in a research note on Tuesday, December 6th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $145.00 target price on shares of Celgene Corporation in a research note on Tuesday, December 20th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, twenty-four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $138.78.

Celgene Corporation Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/kingfisher-capital-llc-invests-1376000-in-celgene-corporation-celg/1657003.html

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *